Novavax, Inc announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% efficacy overall, and met the primary endpoint in its PREVENT-19 pivotal Phase 3 trial. The study enrolled 29,960 participants across 119 sites in the U.S. and Mexico to evaluate efficacy, safety and immunogenicity, with an emphasis on recruiting a representative population of communities and demographic groups most impacted by the disease.
- Read more about Novavax COVID-19 Vaccine 90% efficacy in Phase 3 Trial
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/novavax-covid-19-vaccine-90-percentage-efficacy-in-phase-3-trial
No comments:
Post a Comment